Showing 5101-5110 of 7761 results for "".
- Website Launches for Those Suffering from Acne Scarshttps://practicaldermatology.com/news/20141003-website_launches_for_those_suffering_from_acne_scars/2459097/A new website has launched to help those who suffer from the physical and emotional impacts of acne scarring. “A Scar Free Me” is the first of its kind online community that offers free resources and support for people coping with the aftermath of acne. Visitors can consult with skin car
- Teledermatology App Teams Up with Dermatologistshttps://practicaldermatology.com/news/20141002-teledermatology_company_teams_up_with_dermatologists/2459098/A new teledermatology app is partnering with board- and state-certified dermatologists to assist patients with on-the-spot information regarding the detection and evaluation of skin disease in early stages. Having launched already in 13 states, Klara has partnered up with Dr. Mark Kaufmann, MD, Asso
- Taclonex Granted New Indication for Scalp Plaque Psoriasis in Adolescent Patientshttps://practicaldermatology.com/news/20140930-combination_topical_treatment_approved_for_scalp_plaque_psoriasis_in_adolescent_patients/2459101/LEO Pharma Inc., has received a new indication for Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension for a topical combination treatment of plaque psoriasis of the scalp in patients 12 to 17 years. The new indication represents the first indication for adolescent patients a
- GSK Presents Updated Results from Phase III BREAK-3 Study of Tafinlar® (dabrafenib)https://practicaldermatology.com/news/20140929-gsk_presents_updated_results_from_phase_iii_break-3_study_of_tafinlar_dabrafenib/2459102/Results from the planned analysis of the Phase III BREAK-3 study in 250 patients with BRAF V600E mutant metastatic melanoma show benefit for the use of GSK's Tafinlar (dabrafenib) over dacarbazine (DTIC). Forty-five percent of patients treated with dabrafenib only were alive at two
- Cynosure Receives Expanded FDA Clearance to Market PicoSure for Treatment of Wrinkleshttps://practicaldermatology.com/news/20140924-cynosure_receives_expanded_fda_clearance_to_market_picosure_for_treatment_of_wrinkles/2459105/Cynosure, Inc. has received FDA 510(k) clearance to market its PicoSure Picosecond Laser Workstation for the treatment of wrinkles with the company's new disposable energy delivery system, the FOCUS lens array. In the fourth quarter of 2012, PicoSure recieve
- EAU THERMALE AVÈNE AND KLORANE WIN AT 18th ANNUAL ALLURE BEST OF BEAUTY AWARDS 2014https://practicaldermatology.com/news/20140922-eau_thermale_avne_and_klorane_win_at_18th_annual_allure_best_of_beauty_awards_2014/2459109/In the category of Big Breakthrough, whichacknowledged only 16 winners, Avène earned top honors for the Avène XeraCalm A.D Lipid-Replenishing collection, newly launched in January of this year. In its third consecutive year of being recognized in the Best of Beauty Awards,
- Novan's Nitric Oxide Drug Candidate Inhibits Growth of Papillomavirus in Translational Animal Model: Presentationhttps://practicaldermatology.com/news/20140909-novans_nitric_oxide_drug_candidate_inhibits_growth_of_papillomavirus_in_translational_animal_model_presentation/2459124/Novan Therapeutics, a clinical-stage biotech company focused on advancing nitric oxide therapies, announced that Novan's nitric oxide drug candidate SB206 was shown to inhibit papilloma growth in a preclinical animal study. About two-thirds of healthy American adults are infected with human papillom
- Alphaeon to Acquire Clarion Medical Technologieshttps://practicaldermatology.com/news/20140909-alphaeon_to_acquire_clarion_medical_technologies/2459125/Alphaeon Corporation, a subsidiary of Strathspey Crown Holdings LLC, and Clarion Medical Technologies Inc. entered into a definitive agreement for Alphaeon to acquire all of the outstanding shares and assets of Clarion, a provider of medical and aesthetic equipment and consumabl
- Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agencyhttps://practicaldermatology.com/news/20140904-amgen_submits_marketing_authorization_application_for_talimogene_laherparepvec_to_the_european_medicines_agency/2459130/Amgen recently submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the centralized procedure for talimogene laherparepvec seeking approval for the treatment of adults with melanoma that is regionally or distantly metastatic. Talimogen
- Novan to Present Antiviral Preclinical Results of Nitric Oxide-Releasing Drug Candidates for the Treatment of Papillomavirushttps://practicaldermatology.com/news/20140903-novan_to_present_antiviral_preclinical_results_of_nitric_oxide-releasing_drug_candidates_for_the_treatment_of_papillomavirus/2459131/Novan Therapeutics, a clinical stage biotech company focused on advancing nitric oxide therapies, will present antiviral data from a preclinical animal study at the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), ta